Open AccessSYNTHESIS AND EVALUATION OF SOME NEW 2-(5-(4-BENZAMIDOBENZYLIDENE)-2,4DIOXOTHIAZOLIDIN-3-YL)ACETIC ACID ANALOGS AS ALDOSE REDUCTASE INHIBITORS
Author(s) -
Arun Kumar Gupta,
Jyoti Pandey,
Amjad Ali
Publication year - 2016
Publication title -
asian journal of pharmaceutical and clinical research
Language(s) - English
Resource type - Journals
eISSN - 2455-3891
pISSN - 0974-2441
DOI - 10.22159/ajpcr.2017.v10i1.12073
Subject(s) - aldose reductase , sorbitol , acetic acid , aldehyde reductase , chemistry , diabetes mellitus , enzyme , aldose reductase inhibitor , polyol pathway , reductase , aldose , biochemistry , medicine , stereochemistry , endocrinology , glycoside
Objective: Aldose reductase (ALR) enzyme plays a significant role in conversion of excess amount of glucose into sorbitol in diabetic condition,inhibitors of which decrease the secondary complication of diabetes mellitus. Scarce treatment of diabetic complications has motivated our interestfor the search of new aldose reductase inhibitors (ARIs) endowed with more favorable biological properties.Methods: Newer (4-(benzamidobenzylidene)-2,4-dioxothiazolidin-3-yl) acetic acid derivatives were synthesized, and these compound wereevaluated for their ARI and antidiabetic activity.Results: ARI activity of synthesized compounds was found in the range of 57.8-71.9% at 5µg/mL. Similarly, synthesized compounds decrease bloodglucose level in the range of 64.4-70.5 mg/dl at 15 mg/kg body weight.Conclusion: (E)-2-(5-(4-(substituted benzamido)benzylidene)-2,4-dioxothiazolidin-3-yl)acetic acid analogs shows comparable ARI as well asantidiabetic activity. These new class of compounds might be address the diabetic complications with safety.Keywords: Aldose reductase inhibitors, Diabetes mellitus, N-acetic acid-2,4-thiazolidinediones.